2019 Summit

Thursday, December 12th

Speaker Bios
| Presentation Abstracts

line
8:00 AM – 9:00 AM Breakfast
line
Welcome Remarks
line
9:00 AM – 9:05 AM Jacqueline M. Wolfrum
Associate Director, Biomanufacturing Program, MIT Center for Biomedical Innovation
view bio
line
9:05 AM – 9:25 AM State Investments to Support Biomanufacturing in Massachusetts – From Infrastructure to Innovation
Travis McCready
President and Chief Executive Officer, Massachusetts Life Sciences Center
view bio
line
Keynote Presentation
line
  Morning Chair: Jacqueline M. Wolfrum, MIT CBI, view bio
line
9:25 AM – 10:10 AM Patient-Customized Oligonucleotides and Genomic Medicine
Timothy Yu
Attending Physician, Division of Genetics and Genomics,
Boston Children’s Hospital
view bio | view abstract
line
Session 3: New Therapies, New Questions
line
10:10 AM – 10:40 AM Innovative Approaches and Solutions for Commercializing Novel Therapeutics: A Case Study
Arun Tholudur
Executive Director, Process Development, Amgen
view bio | view abstract
line
10:40 AM – 10:55 AM Continuous Flow Non-Viral Transfection for ex vivo Cell Therapies
Cullen R. Buie
Associate Professor, Mechanical Engineering, Massachusetts Institute of Technology
view bio
line
10:55 AM - 11:10 AM Refreshment Break
line
11:10 AM – 11:40 AM Complex New Modalities Require Advanced Biomanufacturing Platforms: The Case for Exosome Biotherapeutics
Phillip Maderia
Head of Manufacturing Operations, Codiak BioSciences
view bio | view abstract
line
11:40 AM – 12:10 PM Viral Vector-based Heterologous Prime/Boost Immunotherapy Against HLA Class I-Predicted Neoantigens to Drive CD8 T-Cell Responses in Cancer Patients
Vijay Yabannavar
Executive Vice President of Manufacturing and Technical Operations, Gritstone Oncology
view bio | view abstract
line
12:10 PM – 12:40 PM Single-Cell RNA Sequencing and Functional Assessment of Healthy Donor- and Cancer Patient-Derived T and CAR-T Cell
Demetrios Kalaitzidis
Director, Immuno-Oncology, CRISPR Therapeutics
view bio | view abstract


Konstantinos Karagiannis
Lead Bioinformatics Engineer, CRISPR Therapeutics
view bio | view abstract
line
12:40 PM – 1:30 PM Lunch
line
Session 4: Manufacturing Operations and Scalability of ATMPs
line
  Session Chair: James C. Leung, MIT CBI, view bio
line
1:30 PM – 1:50 PM Continuous Perfusion for Scaling Up Lentiviral Vector Production using Transient Transfection and Stable Producer HEK293 Cell Lines
Maurizio Cattaneo
Chief Executive Officer and Founder, Artemis Biosystems
view bio | view abstract
line
1:50 PM – 2:10 PM Process Control Strategy to Mitigate Contamination Risk of an Aseptic Viral Vector Production Process
Keen Chung
Principal Scientist, Pall Biotech, Pall Corporation
view bio | view abstract
line
2:10 PM – 2:30 PM Multi-Dimensional Acoustic Standing Wave Technology for Automated Manufacturing of Cell and Gene Therapies
Bart Lipkens
Chief Technology Officer, Gene Editing & Novel Modalities, MilliporeSigma
view bio | view abstract
line
2:30 PM – 3:00 PM Key Challenges in Translating Cell and Gene Therapies from Development to Clinical Manufacturing
Dominic Clarke
Global Head of Cell Therapy, HemaCare Corporation
view bio | view abstract
line
3:00 PM – 3:20 PM Refreshment Break
line
Session 5: Sustainable Patient Access for ATMPs
line
3:20 PM – 3:50 PM Early Health Technology Assessment of Stem Cell Therapies: Applications for Type 1 Diabetes
Cátia Bandeiras
PhD Graduate in Early Health Technology Assessment of Stem Cell Therapies, MIT Portugal Program in Bioengineering
view bio | view abstract
line
3:50 PM – 4:15 PM New Cures Require New Pricing Policies
Rena M. Conti
Associate Professor, Department of Markets, Public Policy and Law, Questrom School of Business, Boston University
view bio | view abstract
line
4:15 PM – 5:00 PM Precision Financing Solutions for Durable, Potentially Curative Cell and Gene Therapies
Karen Katz
Director, FoCUS Program, MIT Center for Biomedical Innovation
view bio | view abstract
The Total Direct Age-Specific and Lifetime Costs of Healthcare in Commercially Insured Patients with Sickle Cell Disease
Jonathan Salcedo
PhD Candidate,
University of Southern California; Visiting Scholar, FoCUS Program, MIT Center for Biomedical Innovation
view bio | view abstract
line
Closing Remarks
line
5:00 PM – 5:15 PM Stacy L. Springs
Executive Director, Biomanufacturing Initiatives; Senior Director of Programs, MIT Center for Biomedical Innovation
view bio
line
bottom line
MIT CBI BioMAN